| Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab A Magnifico, L Albano, S Campaner, D Delia, F Castiglioni, P Gasparini, ... Clinical Cancer Research 15 (6), 2010-2021, 2009 | 307 | 2009 |
| Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response G Schiroli, A Conti, S Ferrari, L Della Volpe, A Jacob, L Albano, S Beretta, ... Cell stem cell 24 (4), 551-565. e8, 2019 | 257 | 2019 |
| Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 G Schiroli, S Ferrari, A Conway, A Jacob, V Capo, L Albano, T Plati, ... Science translational medicine 9 (411), eaan0820, 2017 | 212 | 2017 |
| DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions A Insinga, A Cicalese, M Faretta, B Gallo, L Albano, S Ronzoni, L Furia, ... Proceedings of the National Academy of Sciences 110 (10), 3931-3936, 2013 | 169 | 2013 |
| Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking S Ferrari, A Jacob, S Beretta, G Unali, L Albano, V Vavassori, D Cittaro, ... Nature biotechnology 38 (11), 1298-1308, 2020 | 125 | 2020 |
| Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells S Ferrari, A Jacob, D Cesana, M Laugel, S Beretta, A Varesi, G Unali, ... Cell Stem Cell 29 (10), 1428-1444. e9, 2022 | 51 | 2022 |
| Protein kinase Cα determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification A Magnifico, L Albano, S Campaner, M Campiglio, S Pilotti, S Ménard, ... Cancer Research 67 (11), 5308-5317, 2007 | 42 | 2007 |
| Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper‐IgM syndrome V Vavassori, E Mercuri, GE Marcovecchio, MC Castiello, G Schiroli, ... EMBO Molecular Medicine 13 (3), e13545, 2021 | 36 | 2021 |
| EGFR through STAT3 modulates ΔN63α expression to sustain tumor‐initiating cell proliferation in squamous cell carcinomas F Ripamonti, L Albano, A Rossini, S Borrelli, S Fabris, R Mantovani, ... Journal of Cellular Physiology 228 (4), 871-878, 2013 | 34 | 2013 |
| Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells A Omer-Javed, G Pedrazzani, L Albano, S Ghaus, C Latroche, M Manzi, ... Cell 185 (13), 2248-2264. e21, 2022 | 29 | 2022 |
| Genotoxic effects of base and prime editing in human hematopoietic stem cells M Fiumara, S Ferrari, A Omer-Javed, S Beretta, L Albano, D Canarutto, ... Nature biotechnology, 1-15, 2023 | 28 | 2023 |
| Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines P Gasparini, G Bertolini, M Binda, A Magnifico, L Albano, M Tortoreto, ... Cancer letters 296 (2), 206-215, 2010 | 15 | 2010 |
| Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells V Vavassori, S Ferrari, S Beretta, C Asperti, L Albano, A Annoni, ... Blood 142 (9), 812-826, 2023 | 11 | 2023 |
| BAR-Seq clonal tracking of gene-edited cells S Ferrari, S Beretta, A Jacob, D Cittaro, L Albano, I Merelli, L Naldini, ... Nature Protocols 16 (6), 2991-3025, 2021 | 10 | 2021 |
| Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness GL Beretta, M De Cesare, L Albano, A Magnifico, N Carenini, E Corna, ... Tumori Journal 102 (2), 144-149, 2016 | 6 | 2016 |
| Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci Transl Med 2017; 9 G Schiroli, S Ferrari, A Conway, A Jacob, V Capo, L Albano | 6 | |
| Gamma knife radiosurgery in patients with Nelson’s syndrome M Losa, M Detomas, M Bailo, LR Barzaghi, L Albano, M Piloni, ... Journal of Endocrinological Investigation, 1-9, 2021 | 4 | 2021 |
| Surgical approaches to in-utero spina bifida repair: A systematic review S Girardelli, PI Cavoretto, M Origoni, G Gaeta, L Albano, S Acerno, ... Ital. J. Gynaecol. Obstet 34 (4), 2022 | 3 | 2022 |
| Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo C Asperti, D Canarutto, S Porcellini, F Sanvito, F Cecere, V Vavassori, ... Molecular Therapy-Methods & Clinical Development 30, 546-557, 2023 | 1 | 2023 |
| 42. Correction of SCID-X1 by targeted genome editing of hematopoietic stem/progenitor cells (HSPC) in the mouse model G Schiroli, P Genovese, V Capo, MC Castiello, L Albano, MC Holmes, ... Molecular Therapy 24, S18-S19, 2016 | 1 | 2016 |
